Giorni e orari vengono fissati accordandosi direttamente con il docente
1) Magherini F., Giannoni E., Raugei G., Cirri P., Paoli P., Modesti A., Camici G., Ramponi G. “Cloning of murine low molecular weight phosphotyrosine protein phosphatase cDNA: identification of a new isoform”, FEBS Letters (1998), 437: 263-266. IF: 3.864
2) Chiti F., Taddei N., Giannoni E., van Nuland N.A.J., Ramponi G., Dobson C.M. “Development of enzymatic activity during protein folding. Detection of a spectroscopically silent native-like intermediate of muscle acylphosphatase.” J. Biol. Chem. (1999), 274: 20151-20158. IF: 5.485
3) Chiarugi P., Cirri P., Taddei L., Giannoni E., Camici G., Manao G., Raugei G., Ramponi G. “The low M(r) protein-tyrosine phosphatase is involved in Rho-mediated cytoskeleton rearrangement after integrin and platelet-derived growth factor stimulation” J. Biol. Chem. (2000), 275(7): 4640-6. IF: 5.485
4) Paoli P., Camici G., Manao G., Giannoni E., Ramponi G. “Acylphosphatase possesses nucleoside triphosphatase and nucleotide diphosphatase activities”, Biochem. J. (2000), 349 (Pt 1): 43-49. IF: 3.766
5) Giannoni E., Cirri P., Paoli P., Fiaschi T., Camici G., Manao G., Raugei G., Ramponi G. “Acylphosphatase is a strong apoptosis inducer in HeLa cell line”, Mol. Cell. Biol. Res. Commun. (2000), 3(5): 264-70.IF: ND
6) Chiarugi P., Fiaschi T., Taddei M.L., Talini D. Giannoni E., Raugei G., Ramponi G. “Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation.” J. Biol. Chem.(2001), 276(36): 33478-87. IF: 5.485
7) Paoli P., Giannoni E., Pescitelli R., Camici G., Manao G., Ramponi G. “Hydrogen peroxide triggers the formation of a disulfide dimer of muscle acylphosphatase and modifies some functional properties of the enzyme.” J. Biol. Chem. (2001) 276(45): 41862-9. IF: 5.485
8) Fiaschi T., Chiarugi P., Buricchi F., Giannoni E., Taddei M.L., Talini D., Cozzi G., Zecchi-Orlandini S., Raugei G., Ramponi G. “LMW-PTP is involved in growth inhibition during cell differentiation” J. Biol. Chem. (2001), 276(52): 49156-63. IF: 5.485
9) Bucciantini M.*, Giannoni E.*, Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Dobson C.M., Stefani M. “Inherent toxicity of polypeptide aggregates suggests a common origin of protein misfolding disease” Nature (2002), 416(6880): 507-11. IF: 69.504
10) Chiarugi P., Cirri P., Taddei M.L., Talini D., Doria L., Fiaschi T., Buricchi F., Giannoni E., Camici G., Raugei G., Ramponi G. “New perspectives in PDGF receptor downregulation: the main role of phosphotyrosine phosphatases” J. Cell. Sci. (2002), 115(Pt 10): 2219-32. IF: 5.235
11) Chiarugi P., Cirri P., Taddei M.L., Giannoni E., Fiaschi T., Buricchi F., Camici G., Raugei G., Ramponi G. “Insight into the role of low molecular weight phosphotyrosine phosphatase (LMW-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling. LMW-PTP controls PDGF-r kinase activity through TYR-857 dephosphorylation” J. Biol. Chem. 2002 Oct 4;277(40):37331-8 IF: 5.485
12) Taddei M.L., Chiarugi P., Cirri P., Buricchi F., Fiaschi T., Giannoni E., Talini D., Cozzi G., Formigli L., Raugei G., Ramponi G. “Beta-catenin interacts with Low-Molecular-Weight Protein Tyrosine Phosphatase leading to cadherin-mediated cell-cell adhesion increase” Cancer Res 2002 Nov 15;62(22):6489-99. IF: 13.312
13) Paoli P., Pazzagli L., Giannoni E., Caselli A., Manao G., Camici G., Ramponi G. “A Nucleophilic Catalysis Step is Involved in the Hydrolysis of Aryl Phosphate Monoesters by Human CT Acylphosphatase.” J. Biol. Chem. 2003 Jan 3; 278(1): 194-9 IF: 5.485
14) Iantomasi T., Favilli F., Catarzi S., Giannoni E., Biagioni C., Vincenzini MT. “Involvement of the tyrosine phosphorylation on GSH transport in NIH3T3 fibroblasts.” IUBMB Life. 2003 Mar;55(3):159-65. IF: 4.709
15) Chiarugi P., Pani G., GiannoniE., Taddei M.L., Colavitti R., Raugei G., Symons M., Borrello S., Galeotti T., Ramponi G. “Reactive oxygen species as essential mediators of cell
adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion” J. Cell. Biol. 2003 Jun 9;161(5):933-44 IF: 8.077
16) Giannoni E., Chiarugi P., Cozzi G., Magnelli L., Taddei M. L., Fiaschi T., Buricchi F., Raugei G., Ramponi G. “LFA-1 mediated T cell adhesion is impaired by Low Molecular Weight phosphotyrosine phosphatase-dependent inhibition of FAK activity” J. Biol. Chem. 2003 Sep 19;278(38):36763-76. IF: 5.485
17) Fiaschi T., Chiarugi P., Buricchi F., Giannoni E., Taddei M. L., Magnelli L., Cozzi G., Raugei G., Ramponi G. “Down-regulation of PDGF receptor signaling during myogenesis.” Cell. Mol. Life. Sc. 2003 Dec;60(12):2721-35 IF: 9.234
18) Chiarugi P., Taddei M. L., Schiavone N., Papucci L., Giannoni E., Capaccioli S., Raugei G., Ramponi G. “LMW-PTP is a positive regulator of tumor onset and growth” Oncogene 2004 May 13;23(22):3905-14. IF: 8.756
19) Ventura S., Zurdo J., Narayanan S., Parreno M., Mangues R., Reif B., Chiti F., Giannoni E., Dobson C.M., Aviles F.X., Serrano L. “Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case.”Proc Natl Acad Sci U S A. 2004 May 11;101(19):7258-63 IF: 12.779
20) Cecchi C., Liguri G., Fiorillo C., Bogani F., Gambassi M., Giannoni E., Cirri P., Baglioni S., Ramponi G. “Acylphosphatase overexpression triggers SH-SY5Y differentiation towards neuronal phenotype.” Cell. Mol. Life Sci. 2004 Jul;61(14):1775-84. IF: 9.234
21)Cirri P., Taddei M.L., Chiarugi P., Buricchi F., Caselli A., Paoli P., Giannoni E., Camici G., Manao G., Raugei G., Ramponi G. “Insulin inhibits PDGF-induced cell proliferation” Mol Biol Cell. 2005 Jan;16(1):73-83. IF: 3.612
22) Chiarugi P. and Giannoni E. “Anchorage-dependent cell growth: tyrosine kinases and phosphatases meet redox regulation” Antioxid Redox Signal. 2005 May-Jun;7(5-6):578-92. IF: 7.468
23) Giannoni E., Buricchi F., Raugei G., Ramponi G., Chiarugi P. “Intracellular Reactive Oxygen Species Activate Src Tyrosine Kinase during Cell Adhesion and Anchorage-Dependent Cell Growth.” Mol Cell Biol. 2005 Aug;25(15):6391-403. IF: 5.094
24) Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G, Chiarugi P. " EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase." J. Biol. Chem. 2005 Oct 7;280(40):34008-18. IF: 5.485
25) Catarzi S, Biagioni C, Giannoni E, Favilli F, Marcucci T, Iantomasi T, Vincenzini MT. "Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase." Biochim Biophys Acta. - Molecular Cell Research 2005 Sep 10;1745(2):166-75. IF: 5.011
26) Buricchi F, Chiarugi P, Fiaschi T, Giannoni E, Magnelli L, Fanti E, Raugei G, Ramponi G. "During muscle ageing the activation of the mitogenic signalling is not sufficient to guarantee cellular duplication." Ital J Biochem. 2005 Sep-Dec;54(3-4):258-67. IF: ND
27) Giannoni E, Raugei G, Chiarugi P, Ramponi G. "A novel redox-based switch: LMW-PTP oxidation enhances Grb2 binding and leads to ERK activation." Biochem Biophys Res Commun. 2006 Sep 22;348(2):367-73. IF: 3.322
28) Catarzi S, Giannoni E, Favilli F, Meacci E, Iantomasi T, Vincenzini MT. "Sphingosine 1-phosphate stimulation of NADPH oxidase activity: Relationship with platelet-derived growth factor receptor and c-Src kinase." Biochim Biophys Acta. - General Subjects 2007 Jun;1770(6):872-83. IF: 4.117
29) Parri M, Buricchi F, Giannoni E, Grimaldi G, Mello T, Raugei G, Ramponi G, Chiarugi P. "Ephrin-A1 activates a SRC/FAK-mediated motility response leading to RHO-dependent ACTINO/MYOSIN contractility." J. Biol. Chem. 2007 Apr 22 IF: 5.485
30) Buricchi F, Giannoni E., Grimaldi G., Parri M., Raugei G, Ramponi G, Chiarugi P. " Redox regulation of Ephrin/Integrin cross-talk" Cell Adhesion & Migration 1:1, 33-42; January/February/March 2007 IF: 3.255
31) Giannoni E, Buricchi F, Grimaldi G, Parri M, Cialdai F, Taddei ML, Raugei G, Ramponi G, Chiarugi P.“Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival.” Cell Death Differ. 2008 May;15(5):867-78. IF: 12.073
32)Chiarugi P. Giannoni E. “Anoikis: a necessary death program for anchorage-dependent cells.” Biochem Pharmacol. 2008 Dec 1;76(11):1352-64. IF: 6.100
33) Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, Calorini L, Rucci N, Teti A, Bologna M, Chiarugi P. "Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.” Am J Pathol. 2009 Apr;174(4):1492-503. IF: 5.770
34) Giannoni E, Fiaschi T, Ramponi G, Chiarugi P. “Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals.” Oncogene. 2009 May 21;28(20):2074-86. IF: 8.756
35) Pani G, Giannoni E, Galeotti T, Chiarugi P. “Redox-based escape mechanism from death: the cancer lesson.” Antioxid Redox Signal. 2009 Nov;11(11):2791-806. IF: 7.468
36) Fiaschi T, Tedesco FS, Giannoni E, Diaz-Manera J, Parri M, Cossu G, Chiarugi P. “Globular adiponectin as a complete mesangioblast regulator: role in proliferation, survival, motility and skeletal muscle differentiation.” Mol Biol Cell. 2010 Mar;21(6):848-59. IF: 3.612
37) Giannoni E, Taddei ML, Chiarugi P. “Src redox regulation: again in the front line.” Free Radic Biol Med. 2010 Aug 15;49(4):516-27. IF: 8.101
38) Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. “Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.” Cancer Res. 2010 Sep 1;70(17):6945-56. IF: 13.312
39) Taddei ML, Parri M, Angelucci A, Bianchini F, Marconi C, Giannoni E, Raugei G, Bologna M, Calorini L, Chiarugi P. “EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.” Mol Cancer Res. 2011 Feb;9(2):149-60. IF: 6.333
40) Giannoni E, Bianchini F, Calorini L, Chiarugi P. “Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness.” Antioxid Redox Signal. 2011 Jun 15;14(12):2361-71. IF: 7.468
41) Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, Migliore C, Giordano S, Chiarugi P. “HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells.” Free Radic Biol Med. 2011 Aug 15;51(4):893-904. IF: 8.101
42) Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. “Anoikis: an emerging hallmark in health and diseases. J Pathol. 2012 Jan;226(2):380-93. IF: 9.883
43) Giannoni E, Parri M, Chiarugi P. “EMT and Oxidative Stress: A Bidirectional Interplay Affecting Tumor Malignancy.” Antioxid Redox Signal. 2012 Jun 1;16(11):1248-63. IF: 7.468
44) Taddei ML, Giannoni E, Raugei G, Scacco S, Sardanelli AM, Papa S, Chiarugi P. “Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness.” J Signal Transduct. 2012;2012:684592. IF 2016: 2.2
45) Bianchini F, Giannoni E, Serni S, Chiarugi P, Calorini L. “22:6n-3 DHA inhibits differentiation of prostate fibroblasts into myofibroblasts and tumorigenesis.” Br J Nutr. 2012 Mar 6:1-9. IF: 4.125
46) Fiaschi T, Giannoni E, Taddei ML, Chiarugi P. “Globular adiponectin activates motility and regenerative traits of muscle satellite cells.” PLoS One. 2012;7(5):e34782. IF: 3.752
47) Comito G, Giannoni E, Di Gennaro P, Segura CP, Gerlini G, Chiarugi P. “Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness.” Cancer Lett. 2012 Nov 1;324(1):31-41. IF: 9.756
48) Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. “Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.” Cancer Res. 2012 Oct 1;72(19):5130-40. IF: 13.312
49) Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, Fibbi G, Mazzanti B, Calorini L, Chiarugi P. “EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.” J Mol Med (Berl). 2013 Jan;91(1):103-15. IF: 5.606
50) Pitozzi V, Mocali A, Laurenzana A, Giannoni E, Cifola I, Battaglia C, Chiarugi P, Dolara P, Giovannelli L. “Chronic Resveratrol Treatment Ameliorates Cell Adhesion and Mitigates the Inflammatory Phenotype in Senescent Human Fibroblasts.” J Gerontol A Biol Sci Med Sci. 2012 Aug 29. IF: 6.591
51) Serratì S, Chillà A, Laurenzana A, Margheri F, Giannoni E, Magnelli L, Chiarugi P, Dotor J, Feijoo E, Bazzichi L, Bombardieri S, Kahaleh B, Fibbi G, Del Rosso M. “Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.” Arthritis Rheum. 2013 Jan;65(1):258-69. IF: 15.483
52) Calvani M, Comito G, Giannoni E, Chiarugi P. “Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species.” PLoS One. 2012;7(10):e38388. IF: 3.752
53) Taddei ML, Giannoni E, Comito G, Chiarugi P. “Microenvironment and tumor cell plasticity: An easy way out.” Cancer Lett. 2013 Nov 28;341(1):80-96. IF: 9.756
54) Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P. “Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells”. Cell Cycle. 2013 May 8;12(11). IF: 5.173
55) Comito G, Giannoni E, Pons Segura C, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S and Chiarugi P “Cancer associated fibroblasts and M2 polarized macrophages synergize during prostate carcinoma progression” Oncogene. 2014 May 8;33(19):2423-31. IF: 8.756
56) Gandellini P*, Giannoni E*, Casamichele A, TaddeiML, Callari C, Valdagni R, Pierotti MA, Zaffaroni N and Chiarugi P “miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts” Antioxid Redox Signal. 2014 Mar 1;20(7):1045-59. IF: 7.468
57) Giannoni E and Chiarugi P “Redox circuitries during cell motility: Src at the leading edge” Antioxid Redox Signal. 2014 May 1;20(13):2011-25. IF: 7.468
58) Paoli P, Giannoni E and Chiarugi P “Anoikis molecular pathways and their role in cancer progression” Biochim Biophys Acta. - Molecular Cell Research 2013 Dec;1833(12):3481-98. IF: 5.011
59) Rapizzi E, Ercolino T, Fucci R, Zampetti B, Felici R, Guasti D, Morandi A, Giannoni E, Giaché V, Bani D, Chiarugi A, Mannelli M. “Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.” Horm Cancer. 2014 Jun;5(3):174-84. IF: 4.667
60) Margheri F, Luciani C, Taddei ML, Giannoni E, Laurenzana A, Biagioni A, Chillà A, Chiarugi P, Fibbi G, Del Rosso M. “The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.” Oncotarget. 2014 Mar 30;5(6):1538-53. IF 2016: 5.168
61) Taddei ML, Giannoni E, Morandi A, Ippolito L, Ramazzotti M, Callari M, Gandellini P, Chiarugi P. “Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells.” Cell Commun Signal. 2014 Apr 1;12:24. IF: 7.540
62) Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, Giannoni E, Carini M, Chiarugi P, Serni S. “The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy.” Biomed Res Int. 2014;2014:486798. IF: 3.246
63) Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. “Senescent stroma promotes prostate cancer progression: the role of miR-210.” Mol Oncol. 2014 Dec;8(8):1729-46. IF: 7.449
64) Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S, Nassini R, Gerlini G, Borgognoni L, Bambi F, Giannoni E, Filippi L, Chiarugi P. “Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression.” Oncotarget. 2015 Mar 10;6(7):4615-32. IF 2016: 5.168
65) Rapizzi E, Fucci R, Giannoni E, Canu L, Richter S, Cirri P, Mannelli M. “Role of microenvironment on neuroblastoma SK-N-AS SDHB silenced cell metabolism and function.” Endocr Relat Cancer. 2015 Mar 25. IF: 5.905
66) Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, Richichi B, Raugei G, Wong N, Tang D, Chiarugi P. “Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.” Oncotarget. 2015 Sep 15;6(27):24061-74. IF 2016: 5.168
67) Maraldi T, Angeloni C, Giannoni E, Sell C “Reactive Oxygen Species in Stem Cells.” Oxid Med Cell Longev. 2015;2015:159080. doi: 10.1155/2015/159080. IF: 7.310
68) Doldi V, Callari M, Giannoni E, D'Aiuto F, Maffezzini M, Valdagni R, Chiarugi P, Gandellini P, Zaffaroni N. “Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation.” Oncotarget. 2015 Oct 13;6(31):31441-60. IF 2016: 5.168
69) Corti D, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, Caselli A, Vanoni M, Landriscina M, Cirri P, Chiarugi P. “5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.” Oncotarget. 2015 Dec 8;6(39):41706-21. IF 2016: 5.168
70) Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, Chiarugi P, Morandi A. “miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.” Cancer Res. 2016 Mar 15;76(6):1615-26. IF: 13.312
71) Comito G, Segura CP, Taddei ML, Lanciotti M, Serni S, Morandi A, Chiarugi P, Giannoni E. “Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.” Oncotarget. 2017 Jan 3;8(1):118-132. IF 2016: 5.168
72) Peppicelli S, Toti A, Giannoni E, Bianchini F, Margheri F, Del Rosso M, Calorini L. “Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation.” Cell Cycle. 2016 Jul 17;15(14):1908-18. IF: 5.173
73) Calvani M, Bianchini F, Taddei ML, Becatti M, Giannoni E, Chiarugi P, Calorini L. “Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits.” Oncotarget. 2016 Aug 9;7(32):51138-51149. IF 2016: 5.168
74) Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, Giannoni E, Schrader T, Puhr M, Chiarugi P, Taddei ML. “Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.” Oncotarget. 2016 Sep 20;7(38):61890-61904. IF 2016: 5.168
75) Morandi A, Giannoni E and Chiarugi P. “Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk” Trends in Cancer, 2016 Dec;2(12):736-746. IF: 19.161
76) Pistore C*, Giannoni E*, Colangelo T, Rizzo F, Magnani E, Muccillo L, Giurato G, Mancini M, Rizzo S, Riccardi M, Sahnane N, Del Vescovo V, Kishore K, Mandruzzato M, Macchi F, Pelizzola M, Denti MA, Furlan D, Weisz A, Colantuoni V, Chiarugi P, Bonapace IM. “DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.” Oncogene. 2017 Jun 5. IF: 8.756
77) Morandi A, Taddei ML, Chiarugi P, Giannoni E “Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors” Front Oncol.2017 Mar 14;7:40. IF: 5.738
78) Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S. “Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.” Cell Metab. 2018 Dec 4;28(6):848-865.e6. doi: 10.1016/j.cmet.2018.08.006. IF: 31.373
79) Taddei ML, Cavallini L, Ramazzotti M, Comito G, Pietrovito L, Morandi A, Giannoni E, Raugei G, Chiarugi P. “Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy.” J Cell Physiol. 2018 Oct 30. doi: 10.1002/jcp.27679. IF: 6.513
80) Ippolito L, Morandi A, Giannoni E, Chiarugi P “Lactate: A Metabolic Driver in the Tumour Landscape.” Trends Biochem Sci. 2019 Feb;44(2):153-166. doi: 10.1016/j.tibs.2018.10.011 IF: 14.264
81) Pietrovito L, Comito G, Parri M, Giannoni E, Chiarugi P, Taddei ML. “Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.” Curr Cancer Drug Targets. 2019 Jan 15. doi: 10.2174/1568009619666190115142858. IF: 2.907
82) Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, Montagnani I, Raspollini MR, Serni S, Simeoni L, Giannoni E, Chiarugi P. “Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis.” Oncogene. 2019 Jan 21. doi: 10.1038/s41388-019-0688-7. IF: 8.756
83) Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, Raspollini MR, Magherini F, Rapizzi E, Masquelier J, Muccioli GG, Sonveaux P, Chiarugi P, Giannoni E. “Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer.” Oncogene. 2019 Apr 1. doi: 10.1038/s41388-019-0805-7. IF: 8.756
84) Bacci M, Ippolito L, Magnelli L, Giannoni E, Chiarugi P. "Stromal-induced mitochondrial re-education: Impact on epithelial-to-mesenchymal transition and cancer aggressiveness.” Semin Cell Dev Biol. 2019 May 21. pii: S1084-9521(18)30218-0. doi: 10.1016/j.semcdb.2019.05.009. IF: 7.499
85) Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A. “Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.” Cell Rep. 2019 Jul 2;28(1):104-118.e8. doi: 10.1016/j.celrep.2019.06.010. IF: 9.995
86) Pietrovito L, Iozzo M, Bacci M, Giannoni E, Chiarugi P. “Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression.” Int J Mol Sci. 2020 Jan 25;21(3). pii: E787. doi: 10.3390/ijms21030787. IF: 6.208
87) Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, Migliaccio I, Malorni L, Chiarugi P, Morandi A. “Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib.” Cells. 2020 Mar 10;9(3). pii: E668. doi: 10.3390/cells9030668. IF: 7.666
88) Ippolito L, Giannoni E, Chiarugi P, Parri M. “Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy.” Front Oncol. 2020 Feb 28;10:256. doi:10.3389/fonc.2020.00256. IF: 5.738
89) Iozzo M, Sgrignani G, Comito G, Chiarugi P, Giannoni E. Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches. Cells. 2021 Dec 2;10(12):3396. doi: 10.3390/cells10123396 IF: 7.666
90) Ippolito L, Comito G, Parri M, Iozzo M, Duatti A, Virgilio F, Lorito N, Bacci M, Pardella E, Sandrini G, Bianchini F, Damiano R, Ferrone L, la Marca G, Serni S, Spatafora P, Catapano CV, Morandi A, Giannoni E, Chiarugi P. Lactate Rewires Lipid Metabolism and Sustains a Metabolic-Epigenetic Axis in Prostate Cancer. Cancer Res. 2022 Apr 1;82(7):1267-1282. doi: 10.1158/0008-5472.CAN-21-0914 IF: 13.312
91) Pardella E, Ippolito L, Giannoni E, Chiarugi P. Nutritional and metabolic signalling through GPCRs. FEBS Lett. 2022 Sep;596(18):2364-2381. doi: 10.1002/1873-3468.14441 IF: 3.864
5) Giannoni E., Cirri P., Paoli P., Fiaschi T., Camici G., Manao G., Raugei G., Ramponi G. “Acylphosphatase is a strong apoptosis inducer in HeLa cell line”, Mol. Cell. Biol. Res. Commun. (2000), 3(5): 264-70. IF: ND
6) Chiarugi P., Fiaschi T., Taddei M.L., Talini D. Giannoni E., Raugei G., Ramponi G. “Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation.” J. Biol. Chem. (2001), 276(36): 33478-87. IF: 5.157
7) Paoli P., Giannoni E., Pescitelli R., Camici G., Manao G., Ramponi G. “Hydrogen peroxide triggers the formation of a disulfide dimer of muscle acylphosphatase and modifies some functional properties of the enzyme.” J. Biol. Chem. (2001) 276(45): 41862-9. IF: 5.157
8) Fiaschi T., Chiarugi P., Buricchi F., Giannoni E., Taddei M.L., Talini D., Cozzi G., Zecchi-Orlandini S., Raugei G., Ramponi G. “LMW-PTP is involved in growth inhibition during cell differentiation” J. Biol. Chem. (2001), 276(52): 49156-63. IF: 5.157
9) Bucciantini M.*, Giannoni E.*, Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Dobson C.M., Stefani M. “Inherent toxicity of polypeptide aggregates suggests a common origin of protein misfolding disease” Nature (2002), 416(6880): 507-11. IF: 49.962
10) Chiarugi P., Cirri P., Taddei M.L., Talini D., Doria L., Fiaschi T., Buricchi F., Giannoni E., Camici G., Raugei G., Ramponi G. “New perspectives in PDGF receptor downregulation: the main role of phosphotyrosine phosphatases” J. Cell. Sci. (2002), 115(Pt 10): 2219-32. IF: 5.285
11) Chiarugi P., Cirri P., Taddei M.L., Giannoni E., Fiaschi T., Buricchi F., Camici G., Raugei G., Ramponi G. “Insight into the role of low molecular weight phosphotyrosine phosphatase (LMW-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling. LMW-PTP controls PDGF-r kinase activity through TYR-857 dephosphorylation” J. Biol. Chem. 2002 Oct 4;277(40):37331-8 IF: 5.157
12) Taddei M.L., Chiarugi P., Cirri P., Buricchi F., Fiaschi T., Giannoni E., Talini D., Cozzi G., Formigli L., Raugei G., Ramponi G. “Beta-catenin interacts with Low-Molecular-Weight Protein Tyrosine Phosphatase leading to cadherin-mediated cell-cell adhesion increase” Cancer Res 2002 Nov 15;62(22):6489-99. IF: 12.701
13) Paoli P., Pazzagli L., Giannoni E., Caselli A., Manao G., Camici G., Ramponi G. “A Nucleophilic Catalysis Step is Involved in the Hydrolysis of Aryl Phosphate Monoesters by Human CT Acylphosphatase.” J. Biol. Chem. 2003 Jan 3; 278(1): 194-9 IF: 5.157
14) Iantomasi T., Favilli F., Catarzi S., Giannoni E., Biagioni C., Vincenzini MT. “Involvement of the tyrosine phosphorylation on GSH transport in NIH3T3 fibroblasts.” IUBMB Life. 2003 Mar;55(3):159-65. IF: 3.885
15) Chiarugi P., Pani G., Giannoni E., Taddei M.L., Colavitti R., Raugei G., Symons M., Borrello S., Galeotti T., Ramponi G. “Reactive oxygen species as essential mediators of celladhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion” J. Cell. Biol. 2003 Jun 9;161(5):933-44 IF: 10.539
16) Giannoni E., Chiarugi P., Cozzi G., Magnelli L., Taddei M. L., Fiaschi T., Buricchi F., Raugei G., Ramponi G. “LFA-1 mediated T cell adhesion is impaired by Low Molecular Weight phosphotyrosine phosphatase-dependent inhibition of FAK activity” J. Biol. Chem. 2003 Sep 19;278(38):36763-76. IF: 5.157
17) Fiaschi T., Chiarugi P., Buricchi F., Giannoni E., Taddei M. L., Magnelli L., Cozzi G., Raugei G., Ramponi G. “Down-regulation of PDGF receptor signaling during myogenesis.” Cell. Mol. Life. Sc. 2003 Dec;60(12):2721-35 IF: 9.261
18) Chiarugi P., Taddei M. L., Schiavone N., Papucci L., Giannoni E., Capaccioli S., Raugei G., Ramponi G. “LMW-PTP is a positive regulator of tumor onset and growth” Oncogene 2004 May 13;23(22):3905-14. IF: 9.867
19) Ventura S., Zurdo J., Narayanan S., Parreno M., Mangues R., Reif B., Chiti F., Giannoni E., Dobson C.M., Aviles F.X., Serrano L. “Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case.” Proc Natl Acad Sci U S A. 2004 May 11;101(19):7258-63 IF: 11.205
20) Cecchi C., Liguri G., Fiorillo C., Bogani F., Gambassi M., Giannoni E., Cirri P., Baglioni S., Ramponi G. “Acylphosphatase overexpression triggers SH-SY5Y differentiation towards neuronal phenotype.” Cell. Mol. Life Sci. 2004 Jul;61(14):1775-84. IF: 9.261
21) Cirri P., Taddei M.L., Chiarugi P., Buricchi F., Caselli A., Paoli P., Giannoni E., Camici G., Manao G., Raugei G., Ramponi G. “Insulin inhibits PDGF-induced cell proliferation” Mol Biol Cell. 2005 Jan;16(1):73-83. IF: 4.138
22) Chiarugi P. and Giannoni E. “Anchorage-dependent cell growth: tyrosine kinases and phosphatases meet redox regulation” Antioxid Redox Signal. 2005 May-Jun;7(5-6):578-92. IF: 8.401
23) Giannoni E., Buricchi F., Raugei G., Ramponi G., Chiarugi P. “Intracellular Reactive Oxygen Species Activate Src Tyrosine Kinase during Cell Adhesion and Anchorage-Dependent Cell Growth.” Mol Cell Biol. 2005 Aug;25(15):6391-403. IF: 4.272
24) Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G, Chiarugi P. " EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase." J. Biol. Chem. 2005 Oct 7;280(40):34008-18. IF: 5.157
25) Catarzi S, Biagioni C, Giannoni E, Favilli F, Marcucci T, Iantomasi T, Vincenzini MT. "Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase." Biochim Biophys Acta. - Molecular Cell Research 2005 Sep 10;1745(2):166-75. IF: 4.739
27) Giannoni E, Raugei G, Chiarugi P, Ramponi G. "A novel redox-based switch: LMW-PTP oxidation enhances Grb2 binding and leads to ERK activation." Biochem Biophys Res Commun. 2006 Sep 22;348(2):367-73. IF: 3.575
28) Catarzi S, Giannoni E, Favilli F, Meacci E, Iantomasi T, Vincenzini MT. "Sphingosine 1-phosphate stimulation of NADPH oxidase activity: Relationship with platelet-derived growth factor receptor and c-Src kinase." Biochim Biophys Acta. - General Subjects 2007 Jun;1770(6):872-83. IF: 3.770
29) Parri M, Buricchi F, Giannoni E, Grimaldi G, Mello T, Raugei G, Ramponi G, Chiarugi P. "Ephrin-A1 activates a SRC/FAK-mediated motility response leading to RHO-dependent ACTINO/MYOSIN contractility." J. Biol. Chem. 2007 Apr 22 IF: 5.157
30) Buricchi F, Giannoni E., Grimaldi G., Parri M., Raugei G, Ramponi G, Chiarugi P. " Redox regulation of Ephrin/Integrin cross-talk" Cell Adhesion & Migration 1:1, 33-42; January/February/March 2007 IF: 3.405
31) Giannoni E, Buricchi F, Grimaldi G, Parri M, Cialdai F, Taddei ML, Raugei G, Ramponi G, Chiarugi P. “Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival.” Cell Death Differ. 2008 May;15(5):867-78. IF: 15.828
32) Chiarugi P. Giannoni E. “Anoikis: a necessary death program for anchorage-dependent cells.” Biochem Pharmacol. 2008 Dec 1;76(11):1352-64. IF: 5.858
33) Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, Calorini L, Rucci N, Teti A, Bologna M, Chiarugi P. "Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.” Am J Pathol. 2009 Apr;174(4):1492-503. IF: 4.307
34) Giannoni E, Fiaschi T, Ramponi G, Chiarugi P. “Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals.” Oncogene. 2009 May 21;28(20):2074-86. IF: 9.867
35) Pani G, Giannoni E, Galeotti T, Chiarugi P. “Redox-based escape mechanism from death: the cancer lesson.” Antioxid Redox Signal. 2009 Nov;11(11):2791-806. IF: 8.401
36) Fiaschi T, Tedesco FS, Giannoni E, Diaz-Manera J, Parri M, Cossu G, Chiarugi P. “Globular adiponectin as a complete mesangioblast regulator: role in proliferation, survival, motility and skeletal muscle differentiation.” Mol Biol Cell. 2010 Mar;21(6):848-59. IF: 4.138
37) Giannoni E, Taddei ML, Chiarugi P. “Src redox regulation: again in the front line.” Free Radic Biol Med. 2010 Aug 15;49(4):516-27. IF: 7.376
38) Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. “Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.” Cancer Res. 2010 Sep 1;70(17):6945-56. IF: 12.701
39) Taddei ML, Parri M, Angelucci A, Bianchini F, Marconi C, Giannoni E, Raugei G, Bologna M, Calorini L, Chiarugi P. “EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.” Mol Cancer Res. 2011 Feb;9(2):149-60. IF: 5.852
40) Giannoni E, Bianchini F, Calorini L, Chiarugi P. “Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness.” Antioxid Redox Signal. 2011 Jun 15;14(12):2361-71. IF: 8.401
41) Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, Migliore C, Giordano S, Chiarugi P. “HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells.” Free Radic Biol Med. 2011 Aug 15;51(4):893-904. IF: 7.376
42) Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. “Anoikis: an emerging hallmark in health and diseases. J Pathol. 2012 Jan;226(2):380-93. IF: 7.996
43) Giannoni E, Parri M, Chiarugi P. “EMT and Oxidative Stress: A Bidirectional Interplay Affecting Tumor Malignancy.” Antioxid Redox Signal. 2012 Jun 1;16(11):1248-63. IF: 8.401
45) Bianchini F, Giannoni E, Serni S, Chiarugi P, Calorini L. “22:6n-3 DHA inhibits differentiation of prostate fibroblasts into myofibroblasts and tumorigenesis.” Br J Nutr. 2012 Mar 6:1-9. IF: 3.718
46) Fiaschi T, Giannoni E, Taddei ML, Chiarugi P. “Globular adiponectin activates motility and regenerative traits of muscle satellite cells.” PLoS One. 2012;7(5):e34782. IF: 3.240
47) Comito G, Giannoni E, Di Gennaro P, Segura CP, Gerlini G, Chiarugi P. “Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness.” Cancer Lett. 2012 Nov 1;324(1):31-41. IF: 8.679
48) Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. “Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.” Cancer Res. 2012 Oct 1;72(19):5130-40. IF: 12.701
49) Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, Fibbi G, Mazzanti B, Calorini L, Chiarugi P. “EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.” J Mol Med (Berl). 2013 Jan;91(1):103-15. IF: 4.599
50) Pitozzi V, Mocali A, Laurenzana A, Giannoni E, Cifola I, Battaglia C, Chiarugi P, Dolara P, Giovannelli L. “Chronic Resveratrol Treatment Ameliorates Cell Adhesion and Mitigates the Inflammatory Phenotype in Senescent Human Fibroblasts.” J Gerontol A Biol Sci Med Sci. 2012 Aug 29. IF: 6.053
51) Serratì S, Chillà A, Laurenzana A, Margheri F, Giannoni E, Magnelli L, Chiarugi P, Dotor J, Feijoo E, Bazzichi L, Bombardieri S, Kahaleh B, Fibbi G, Del Rosso M. “Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.” Arthritis Rheum. 2013 Jan;65(1):258-69. IF: 10.995
52) Calvani M, Comito G, Giannoni E, Chiarugi P. “Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species.” PLoS One. 2012;7(10):e38388. IF: 3.240
53) Taddei ML, Giannoni E, Comito G, Chiarugi P. “Microenvironment and tumor cell plasticity: An easy way out.” Cancer Lett. 2013 Nov 28;341(1):80-96. IF: 8.679
54) Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P. “Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells”. Cell Cycle. 2013 May 8;12(11). IF: 4.534
55) Comito G, Giannoni E, Pons Segura C, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S and Chiarugi P “Cancer associated fibroblasts and M2 polarized macrophages synergize during prostate carcinoma progression” Oncogene. 2014 May 8;33(19):2423-31. IF: 9.867
56) Gandellini P*, Giannoni E*, Casamichele A, Taddei ML, Callari C, Valdagni R, Pierotti MA, Zaffaroni N and Chiarugi P “miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts” Antioxid Redox Signal. 2014 Mar 1;20(7):1045-59. IF: 8.401
57) Giannoni E and Chiarugi P “Redox circuitries during cell motility: Src at the leading edge” Antioxid Redox Signal. 2014 May 1;20(13):2011-25. IF: 8.401
58) Paoli P, Giannoni E and Chiarugi P “Anoikis molecular pathways and their role in cancer progression” Biochim Biophys Acta. - Molecular Cell Research 2013 Dec;1833(12):3481-98. IF: 4.739
59) Rapizzi E, Ercolino T, Fucci R, Zampetti B, Felici R, Guasti D, Morandi A, Giannoni E, Giaché V, Bani D, Chiarugi A, Mannelli M. “Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.” Horm Cancer. 2014 Jun;5(3):174-84. IF: 3.869
61) Taddei ML, Giannoni E, Morandi A, Ippolito L, Ramazzotti M, Callari M, Gandellini P, Chiarugi P. “Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells.” Cell Commun Signal. 2014 Apr 1;12:24. IF: 5.712
62) Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, Giannoni E, Carini M, Chiarugi P, Serni S. “The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy.” Biomed Res Int. 2014;2014:486798. IF: 3.411
63) Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. “Senescent stroma promotes prostate cancer progression: the role of miR-210.” Mol Oncol. 2014 Dec;8(8):1729-46. IF: 6.603
65) Rapizzi E, Fucci R, Giannoni E, Canu L, Richter S, Cirri P, Mannelli M. “Role of microenvironment on neuroblastoma SK-N-AS SDHB silenced cell metabolism and function.” Endocr Relat Cancer. 2015 Mar 25. IF: 5.678
67) Maraldi T, Angeloni C, Giannoni E, Sell C “Reactive Oxygen Species in Stem Cells.” Oxid Med Cell Longev. 2015;2015:159080. doi: 10.1155/2015/159080. IF: 6.543
70) Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, Chiarugi P, Morandi A. “miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.” Cancer Res. 2016 Mar 15;76(6):1615-26. IF: 12.701
72) Peppicelli S, Toti A, Giannoni E, Bianchini F, Margheri F, Del Rosso M, Calorini L. “Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation.” Cell Cycle. 2016 Jul 17;15(14):1908-18. IF: 4.534
75) Morandi A, Giannoni E and Chiarugi P. “Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk” Trends in Cancer, 2016 Dec;2(12):736-746. IF: 14.226
76) Pistore C*, Giannoni E*, Colangelo T, Rizzo F, Magnani E, Muccillo L, Giurato G, Mancini M, Rizzo S, Riccardi M, Sahnane N, Del Vescovo V, Kishore K, Mandruzzato M, Macchi F, Pelizzola M, Denti MA, Furlan D, Weisz A, Colantuoni V, Chiarugi P, Bonapace IM. “DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.” Oncogene. 2017 Jun 5. IF: 9.867
77) Morandi A, Taddei ML, Chiarugi P, Giannoni E “Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors” Front Oncol. 2017 Mar 14;7:40. IF: 6.244
78) Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S. “Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.” Cell Metab. 2018 Dec 4;28(6):848-865.e6. doi: 10.1016/j.cmet.2018.08.006. IF: 27.287
79) Taddei ML, Cavallini L, Ramazzotti M, Comito G, Pietrovito L, Morandi A, Giannoni E, Raugei G, Chiarugi P. “Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy.” J Cell Physiol. 2018 Oct 30. doi: 10.1002/jcp.27679. IF: 6.384
80) Ippolito L, Morandi A, Giannoni E, Chiarugi P “Lactate: A Metabolic Driver in the Tumour Landscape.” Trends Biochem Sci. 2019 Feb;44(2):153-166. doi: 10.1016/j.tibs.2018.10.011 IF: 13.807
81) Pietrovito L, Comito G, Parri M, Giannoni E, Chiarugi P, Taddei ML. “Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.” Curr Cancer Drug Targets. 2019 Jan 15. doi: 10.2174/1568009619666190115142858. IF: 3.428
82) Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, Montagnani I, Raspollini MR, Serni S, Simeoni L, Giannoni E, Chiarugi P. “Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis.” Oncogene. 2019 Jan 21. doi: 10.1038/s41388-019-0688-7. IF: 9.867
83) Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, Raspollini MR, Magherini F, Rapizzi E, Masquelier J, Muccioli GG, Sonveaux P, Chiarugi P, Giannoni E. “Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer.” Oncogene. 2019 Apr 1. doi: 10.1038/s41388-019-0805-7. IF: 9.867
84) Bacci M, Ippolito L, Magnelli L, Giannoni E, Chiarugi P. "Stromal-induced mitochondrial re-education: Impact on epithelial-to-mesenchymal transition and cancer aggressiveness.” Semin Cell Dev Biol. 2019 May 21. pii: S1084-9521(18)30218-0. doi: 10.1016/j.semcdb.2019.05.009. IF: 7.727
85) Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A. “Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.” Cell Rep. 2019 Jul 2;28(1):104-118.e8. doi: 10.1016/j.celrep.2019.06.010. IF: 9.423
86) Pietrovito L, Iozzo M, Bacci M, Giannoni E, Chiarugi P. “Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression.” Int J Mol Sci. 2020 Jan 25;21(3). pii: E787. doi: 10.3390/ijms21030787. IF: 5.923
87) Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, Migliaccio I, Malorni L, Chiarugi P, Morandi A. “Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib.” Cells. 2020 Mar 10;9(3). pii: E668. doi: 10.3390/cells9030668. IF: 6.600
88) Ippolito L, Giannoni E, Chiarugi P, Parri M. “Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy.” Front Oncol. 2020 Feb 28;10:256. doi:10.3389/fonc.2020.00256. IF: 6.244
Elisa Giannoni è Professore Ordinario di Biochimica (BIO/10) presso la Scuola di Scienze della Salute Umana dell’Università di Firenze ed afferente al Dipartimento di Scienze Biomediche Sperimentali e Cliniche.
1997- consegue la Laurea in Scienze Biologiche presso l'Università degli Studi di Firenze.
1997-1998- svolge il tirocinio post-laurea presso il Dipartimento di Scienze Biochimiche dell'Università degli Studi di Firenze.
1998- sostiene e supera l’Esame di Stato per il conseguimento dell’Abilitazione alla professione di Biologo.
2002- ottiene il titolo di Dottorato di Ricerca in Biochimica.
2002-2005- ottiene un assegno di ricerca da svolgersi presso il Dipartimento di Scienze Biochimiche dell'Università degli Studi di Firenze.
2005- prende servizio come Professore Associato nel settore scientifico disciplinare M-EDF/01 Metodi e Didattiche delle Attività Motorie e prende afferenza presso il Dipartimento di Scienze Biochimiche.
2013- ottiene il passaggio di SSD da M-EDF/01 (Metodi e Didattiche delle Attività Motorie) a BIO/10 (Biochimica) e si incardina nel ruolo di Professore Associato nel settore scientifico disciplinare BIO/10.
2023- ottiene la progressione di carriiera a Professore Odinario nel settore scientifico disciplinare BIO/10.
Elisa Giannoni ha una solida esperienza nel campo della ricerca oncologica. Ha studiato per 5 anni il ruolo dello stress ossidativo nel cancro, portando all'identificazione delle proteine regolate dalla generazione di stresso ossidativo durante la proliferazione cellulare e l'adesione cellulare alla matrice extracellulare. Ha inoltre contribuito agli studi sulla proliferazione ancoraggio-indipendente e sulla resistenza all'anoikis delle cellule tumorali e sulla delucidazione dei mediatori di segnalazione che contribuiscono al raggiungimento di queste capacità. Nell'ultimo decennio, il suo interesse si è concentrato sullo studio del microambiente tumorale, concentrandosi in particolare sui fibroblasti associati al cancro, sulle cellule endoteliali e sulle cellule immunitarie (macrofagi associati al cancro e linfociti infiltranti il tumore). In particolare, ha studiato la plasticità della motilità delle cellule tumorali (come transizione epiteliale-mesenchimale o transizione mesenchimale-ameboide), identificando importanti processi molecolari che guidano questo processo. Più recentemente, ha concentrato i suoi studi sulla plasticità metabolica delle cellule tumorali dovuta all'interazione con il microambiente tumorale, con un interesse particolare all'impatto della riprogrammazione metabolica indotta dallo stroma sulla regolazione epigenetica della malignità delle cellule tumorali.
L'obiettivo generale della ricerca condotta dal suo team è la scoperta di strategie innovative per il trattamento del cancro basate su una profonda conoscenza della complessa interazione tra i processi epigenetici, trascrizionali e metabolici alla base dello sviluppo del cancro.
I risultati rilevanti dei suoi studi sono stati pubblicati su riviste internazionali e contribuiscono a migliorare la conoscenza sui meccanismi molecolari che sono alla base della patogenesi e della progressione dei tumori umani.
Elisa Giannoni è membro del comitato editoriale di riviste internazionali tra cui Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Cells and Cancers. È stata anche redattrice per Hindawi Publishing Corporation, “Oxidative Medicine and Cellular Longevity” - Numero speciale “ROS and Stem Cell”.
Svolge anche il ruolo di revisore per riviste scientifiche internazionali (tra cui Cancer Research, eLife, Journal of Cell Biology, Science Signaling, Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Cells and Cancers).
Elisa Giannoni è membro della Società Italiana di Biochimica (SIB), della Società Italiana di Cancerologia (SIC), dell'Associazione Europea di Ricerca sul Cancro (EACR) e dell'America Association of Cancer Research (AACR). È inoltre membro del comitato scientifico dell'Università di Firenze per le borse di studio dal 2017 e membro del comitato scientifico per la valutazione delle Sir Henry Wellcome Postdoctoral Fellowships (UK).
Elisa Giannoni ha ricevuto finanziamenti da enti finanziatori nazionali e tra i recenti:
- MIUR (PRIN2022 PNRR): “Role of lactate as a metabolic regulator of ferroptosis sensitivity and metastatic dissemination in cancer cells” (2023-2025) - RESPONSABILE DELL'UNITÀ DI RICERCA
- MIUR (PRIN2022): “Metabolic alterations and immune escape in colorectal cancer: activity metabolomics as a novel therapeutic approach” (2023-2025) - RESPONSABILE DELL'UNITÀ DI RICERCA
- MUR Piano Nazionale di Ripresa e Resilienza, Missione 4 Componente 2 - Investimento 1.4 Potenziamento strutture di ricerca e creazione di "campioni nazionali di R&S" su alcune Key Enabling Technologies - finanziato dall’Unione europea – NextGenerationEU - Spoke 2 - Cancer - CN 3 - Centro nazionale di Ricerca Sviluppo di terapia genica e farmaci con tecnologia a RNA (2022-2025) – COORDINATORE DEL PROGETTO DI RICERCA
- Progetti di ricerca competitivi della durata di 30 mesi nell'ambito delle tematiche del PNR 2021-2027 Bando di Ateneo (2023-2026) PARTECIPANTE
- MUR - Excellent Departments- Gender Medicine Program: “Gender impact on the metabolic-related immune surveillance in melanoma” (2020-2022) - COORDINATORE DEL PROGETTO DI RICERCA
- Associazione Italiana Ricerca contro il Cancro (AIRC - Investigator Grant 2020): “Deciphering the lactate-driven metabolic and epigenetic reprogramming in prostate cancer” (2020-2025) PARTECIPANTE
- MIUR (PRIN2017): “Role of nutrients in the epigenetic control of prostate cancer progression” (2018-2022) PARTECIPANTE
- Associazione Italiana Ricerca contro il Cancro (AIRC - Investigator Grant 2015) “Metabolic deregulation towards OXPHOS in malignant cancers: role of miRNAs” (2016-2019) PARTECIPANTE
- Fondazione Umberto Veronesi: RESPONSABILE SCIENTIFICO per un Contratto di Ricerca conferito alla Dr. Comito Giuseppina sul progetto: “Role of tumor microenvironment in immune modulation during prostate carcinoma progression”.
Ad oggi Elisa Giannoni conta 91 pubblicazioni su riviste peer-review, con un Impact Factor (IF) totale di 695.8 (IF medio per pubblicazione: 7,64), un numero totale di citazioni di 10.705 e un H-index di 48 (Scopus).
Legenda
Elisa Giannoni is Associate Professor in Biochemistry in the Human Health Medical School of the University of Florence and works at the Dept. Experimental and Clinical Biomedical Sciences of Florence.
1973- Born in December 1st 1973 in Empoli (FI).
1997- Degree in Biological Sciences to the University of Florence.
1997-1998- Post-degree assistant at the Department of Biochemistry of the University of Florence.
2002- PhD in Biochemistry.
2002-2005- Fellowship at the Department of Biochemistry of the University of Florence.
2005- Associate Professor ofn Metodi e Didattiche delle Attività Motorie (SSD MEDF/01) to the Faculty of Medicine and Surgery in the University of Florence.
2013- Associate Professor of Biochemistry (SSD BIO/10) in the Human Health Medical School of the University of Florence.
2023- Full Professor of Biochemistry (SSD BIO/10) in the Human Health Medical School of the University of Florence.
Elisa Giannoni has a solid expertise in the field of Oncology Research. She has studied for up to 5 years the role of oxidative stress in cancer, leading to the identification of the redox-regulated proteins during cell proliferation and cell adhesion to extracellular matrix. She also contributed to the studies on anchorage independence and anoikis resistance of cancer cells and on the elucidation of the signalling mediators that contributes to the achievement of these skills. In the last decade, her interest focused on the study of tumour microenvironment, particularly focusing on cancer-associated fibroblasts, endothelial cells and immune cells (cancer associated macrophages and tumor infiltrating lymphocytes). In particular, she investigated the plasticity of cancer cell motility (as epithelial-mesenchymal transition or mesenchymal-amoeboid transition), attempting to dissect the molecular signature driving this process. More recently, she has focused her studies on the metabolic plasticity of cancer cells due to the interaction with tumour microenvironment, with a special interest on the impact of the stromal-induced metabolic reprogramming on the epigenetic regulation of cancer cell malignancy.
The overall objective of the research conducted by her team is the discovery of innovative strategies for treatment of cancer based on a deep knowledge of the complex interplay between the epigenetic, transcriptional and metabolic processes underpinning cancer development.
The relevant findings of her studies were published in international peer-reviewed journals and contribute to improve the knowledge on the molecular mechanisms that underline the pathogenesis and progression of human cancers.
Elisa Giannoni is Member of the Editorial Board of international journals including Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Cells and Cancers. She was also Editor for Hindawi Publishing Corporation, “Oxidative Medicine and Cellular Longevity” - Special Issue “ROS and Stem Cell”.
She also serves as reviewer for international scientific journals (including Cancer Research, eLife, Journal of Cell Biology, Science Signaling, Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Cells and Cancers).
Elisa Giannoni is Member of the Italian Society of Biochemistry (SIB), the Italian Society of Cancerology (SIC), the European Association of Cancer Research (EACR) and the America Association of Cancer Research (AACR). She is also Member of the Scientific Committee of the University of Florence for the award grants since 2017 and Member of the Scientific Committee for Sir Henry Wellcome Postdoctoral Fellowships (UK) evaluation.
Elisa Giannoni received funding from national funding agencies and among the recent ones:
- MIUR (PRIN2022 PNRR): “Role of lactate as a metabolic regulator of ferroptosis sensitivity and metastatic dissemination in cancer cells” (2023-2025) - PRINCIPAL INVESTIGATOR OF RESEARCH UNIT
- MIUR (PRIN2022): “Metabolic alterations and immune escape in colorectal cancer: activity metabolomics as a novel therapeutic approach” (2023-2025) - PRINCIPAL INVESTIGATOR OF RESEARCH UNIT
- MUR Piano Nazionale di Ripresa e Resilienza, Missione 4 Componente 2 - Investimento 1.4 Potenziamento strutture di ricerca e creazione di "campioni nazionali di R&S" su alcune Key Enabling Technologies - finanziato dall’Unione europea – NextGenerationEU - Spoke 2 - Cancer - CN 3 - Centro nazionale di Ricerca Sviluppo di terapia genica e farmaci con tecnologia a RNA (2022-2025) - PRINCIPAL INVESTIGATOR
- Progetti di ricerca competitivi della durata di 30 mesi nell'ambito delle tematiche del PNR 2021-2027 Bando di Ateneo (2023-2026) PARTICIPANT
- MUR - Excellent Departments- Gender Medicine Program: “Gender impact on the metabolic-related immune surveillance in melanoma” (2020-2022) PRINCIPAL INVESTIGATOR
- Associazione Italiana Ricerca contro il Cancro (AIRC - Investigator Grant 2020): “Deciphering the lactate-driven metabolic and epigenetic reprogramming in prostate cancer” (2020-2025) PARTICIPANT
- MIUR (PRIN2017): “Role of nutrients in the epigenetic control of prostate cancer progression” (2018-2022) PARTICIPANT
- Associazione Italiana Ricerca contro il Cancro (AIRC - Investigator Grant 2015) “Metabolic deregulation towards OXPHOS in malignant cancers: role of miRNAs” (2016-2019) PARTICIPANT
- Fondazione Umberto Veronesi: SCIENTIFIC SUPERVISOR for a Research Contract conferred to Dr. Comito Giuseppina on the project: “Role of tumor microenvironment in immune modulation during prostate carcinoma progression”.
To date, Elisa Giannoni has 91 publications in peer-review journals, with a total Impact Factor (IF) of 695.8 (average IF/paper: 7.64), a total number of citations of 10.705 and an H index of 48 (Scopus).